Morgan Stanley Assigns Overweight Rating to Sana Biotechnology with $12 Price Target

Morgan Stanley has upgraded Sana Biotechnology (SANA) to an "Overweight" rating, with a price target of $12.00. The company's innovative approach in the biotechnology industry is expected to drive significant strides. Based on 6 analysts' one-year price targets, the average target price is $9.33, indicating an upside of 192.58% from the current price. The consensus recommendation from 8 brokerage firms is "Outperform" with a rating scale ranging from 1 to 5.